News

Assembly Bio’s established areas of research is focused on herpesviruses (HSV), hepatitis B virus and hepatitis D virus.

The increase is close to inflation and wage growth but much steeper than the atypically small increase in 2022.

Patient affordability and access to specialty drugs and cell and gene therapies are just a couple of priorities self-insured employers should keep in mind when managing specialty spend, according to Shawna Ricker, PharmD, clinical pharmacist consultant of Clinical Client Strategy at Highmark, Inc.

Melissa Andel, M.P.P., of CommonHealth Solutions LLC, says there has been some retreat from earlier proposals for severe regulation to an emphasis on disclosure and transparency.

Melissa Andel, M.P.P., of CommonHealth Solutions LLC, thumbnailed the four pieces of legislation advancing through Congress that would tighten regulation and oversight of pharmacy benefit managers (PBMs).

Mark Dybul, M.D., the keynote speaker for the closing session of the IDWeek meeting in Boston, delivered an impassioned defense of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) as its reauthorization by Congress has got ensnarled in abortion issues.

Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center spoke about the phase 3 trial of Moderna’s mRNA vaccine against CMV and another candidate being developed by Merck that showed some promise in a phase 2B trial.

Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says lack of awareness and funding as well as some characteristics of the virus itself have slowed development of vaccine against CMV.

Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says the epidemiology of congenital CMV hasn’t varied much over the years and that the condition does disproportionately affect lower socioeconomic populations and communities of color in the U.S.

Two-thirds of patients with renal comorbidities achieved “clinical success” with the new fecal microbiota treatment for C. difficile.

At this year’s ID Week conference in Boston, Igho Ofotokun, MD, MSc, FIDSA, Grady Distinguished Professor of Medicine at the Emory University School of Medicine, shared the latest data that COVID-19 research team, RECOVER, has gathered on Long COVID and its symptoms.

Laws since 1996 have sought to assure that coverage of behavioral health treatments does not take a back seat to physical medicine. Amid a national crisis in mental illness and addiction, that new world of equality has not arrived. But is it on the way?

The chair of Harvard Medical School’s bioinformatics department says the deterministic, discrete data of billing and reimbursement means that artificial intelligence’s first big impact in healthcare is likely to be in “the business of healthcare.”

The new chief scientific officer of the Crohn’s and Colitis Foundation talked about what motivated him to pursue a career researching and taking care of Crohn’s and colitis patients.

Two drugs that target the c-MET protein are in phase 3 trials.

Payers and hospitals are at odds over proposals that would level out payments to hospital outpatient departments and physician offices.

Patterns in COVID-19 vaccinations remain largely divided along political party lines, according to one report.

Last week, a judge struck down a 2021 federal rule that allowed insurance companies to exclude pharmaceutical company copay assistance from annual deductibles.

Children with atopic dermatitis (AD) are more likely than children without AD to react to a patch test and should be referred to a specialist for evaluation.

Here’s what you need to know and do considering the DOJ’s and HHS’s drastically expanded use of digital tools to investigate and prosecute those who work in the field of healthcare, including innocent practices and providers.

The FDA approved the first biosimilar of the arthritis medication Actemra, as well as plaque psoriasis drug Zoryve for children. The agency issued a complete response letter for lebrikizumab in atopic dermatitis and for liquid formulation of botulinum toxin for frown lines, and assigned a review date for a gene therapy for a rare immune disorder. Additionally, Takeda plans to withdraw the oncology drug Exkivity from the market while Coherus resubmits BLA for Udenyca OnBody.

Authors of a recent review express that ferroptosis inhibition may be a promising pathway for treating and preventing male reproductive disorders.

A hemophilia expert makes some comparisons between the two approved gene therapies for hemophilia.

A new review and analysis suggests a combination treatment regimen for children in acute liver failure due to autoimmune hepatitis may help them maintain native liver survival.